APPLICATIONS PUBLISHED 16 MARCH 2005

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492

Triggered start products and processes for the production and use thereof
OMS Investments 1511469*

A process for preparing a pharmaceutical active ingredient with high specific surface area
Teva Pharmaceutical Industries 1511470*

Colloidal suspension of submicronic particles and method for preparing the same
Flamel Technologies 1511471*

Compounds useful in the treatment of anthrax and limiting lethal factor
Merck 1511472*

Bis-aromatic alkanols
Novartis 1511473*

A method of treatment
The Walter & Eliza Hall Institute of Medical Research 1511474*

A herbal molecule as potential anti-leukaemic drug
Council of Scientific and Industrial Research 1511475*

Scorpionate-like pendant macrocyclic ligands, complexes and compsns thereof, and methods of using same
The Government of the United States of America, represented by the Department of Health & Human Services 1511476*

Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
Errant Gene Therapeutics 1511477*

Triptolide derivatives for modulation of apoptosis and immunosuppression
Pharmagenesis 1511478*

Treatment of neuropathic pain
Abbott Laboratories 1511479*

Inhibitors of glycoprotein VI
Procorde 1511480*

Ophthalmological use of roflumilast for the treatment of diseases of the eye
Altana Pharma 1511481*

2-ureido-6-heteroaryl-3H-benzoimidazole-4-abcroxylic acid derivatives and related compounds as gyrase and/or topoisomerase IV inhibitors for the treatment of bacterial infections
Vertex Pharmaceuticals 1511482*

Methods of treatment with LXR modulators
SmithKline Beecham 1511483*

Combination of a DPP IV inhibitor and a cardiovascular compound
Novartis 1511484*

Novel uses of DL-THP
Xue, Horg; Law, Sek Lun 1511485*

Use of the dopamine partial agonists for the treatment of the restless legs syndrome and corresponding pharmaceutical preparation
NeuroBiotec 1511486*

Novel formulation for the parenteral application of crobenetine
Boehringer Ingelheim Pharma 1511487*

Human adam-10 inhibitors
Exelixis 1511488*

New pharmaceutical compsns containing flibanserin polymorph A
Boehringer Ingelheim Pharma 1511489*

Novel conazole crystalline forms and related processes, pharmaceutical compsns and methods
Transform Pharmaceuticals 1511490*

Derivatives of azepine and thiazepan as interleukin converting enzyme inhibitors
The Procter & Gamble Company 1511491*

Protease inhibitors
SmithKline Beecham 1511492*

Use of peroxovanadium compounds as tumour cell growth suppressor
Universite Laval 1511493*

Androgen pharmaceutical compsn and method for treating depression
Unimed Pharmaceuticals; Laboratoires Besins International 1511494*

Progestagenic dosage units
Akzo Nobel 1511495*

Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
Pantarhei Bioscience 1511496*

Treatment of post-menopausal complaints in breast cancer patients which comprises tibolone and a serm
Akzo Nobel 1511497*

A method of treating human skin and a skin care compsn for use in such a method
Pantarhei Bioscience 1511498*

Immunomodulatory compounds and methods of use thereof
Eisai 1511499*

Combination of anti-muscarinic agents and non-glucocorticoid steroids
Epigenesis Pharmaceuticals 1511500*

A stable bicarbonate-based solution in a single container
Baxter International 1511501*

Probiotic therapies using lactobacillus reuteri
Alimentary Health 1511502*

Use of a preparation produced from plant seedlings, enriched with electrolyte
Vis-Vitalis Lizenz- und Handels 1511503*

Anti-helicobacter activity of celery seed extract
Sheffield Hallam University 1511504*

Novel therapies and methods of screening for therapeutic compounds
Svanborg, Catharina 1511505*

Compsns and methods for preventing, treating and diagnosing diabetes
Metabolex 1511506*

Cell-permeable peptide inhibitors of the JNK signal transduction pathway
Universite de Lausanne 1511507*

Method of treating dyslipidemic disorders
Esperion Therapeutics 1511508*

Compsns and methods for treating diabetes
Waratah Pharmaceuticals 1511509*

Use of UK114 in the treatment of leishmaniasis
Pharmaproducts UK 1511510*

Use of IL-19, IL-22 and IL-24 to treat hematopoietic disorders
Eli Lilly 1511511*

Novel uses of parapoxvirus preparations
Bayer HealthCare 1511512*

Immunogenic compsn s comprising a xenogenic prostate protein P501S
GlaxoSmithKline Biologicals; Glaxo Group 1511513*

FP receptor antagonists or PGF-2 alpha antagonists for treating pathological conditions of the uterus
Medical Research Council 1511514*

Stimulation of hematopoeisis by ex vivo activated immune cells
Yang, Demao 1511515*

Topically pure applicable pharmaceutical preparation
Altana Pharma 1511516*

Formation of parenteral administration of sodium channel blockers
Boehringer Ingelheim Pharma 1511517*

Neutrophil imaging methods in cystic fibrosis
Immunomedics 1511518*

Modified byrodin 1 with reduced immunogenicity
Merck Patent 1511519*

Compsns and methods for the use of BCL-2 transfected neurons
Haglid, Kenneth 1511520*

Strontium-apatitie-cement-preparations and the use thereof
Kryphon 1511521*

Compounds, compsns and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type-2 diabetes and Parkinson's disease
Proteotech 1511710*

Histone deactylase inhibitors based on trihalomethylcarbonyl compounds
Errant Gene Therapeutics 1511715*

Glucocorticoid mimetics, methods of making them, pharmaceutical compsns, and uses thereof
Boehringer Ingelheim Pharmaceuticals 1511716*

Crystalline form of nateglinide
Teva Pharmaceutical Industries 1511717*

N-acylaminobenzene derivatives as selective oxidase B inhibitors
F Hoffmann-La Roche 1511718*

Amide derivatives as inhibitors of the enzymatic activity of renin
Novartis 1511719*

Method of reducing the content of an unsaturated amine in a mixture containing an amino nitrile, a diamine or mixtures thereof
BASF 1511720*

Guanidino phenylalanin compounds used as urokinase inhibitors
Wilex 1511721*

Phenylcyclohexylpropanolamine derivatives, preparation and therapeutic application thereof
Sanofi-Aventis 1511722*

Sulphone liver X-receptor modulators
Pharmacia 1511723*

Process for the preparation of thioalkylamine derivatives
Bayer CropScience 1511724*

24-sulphoximine vitamin D3 derivate
Johns Hopkins University 1511725*

Method for preparing 1,3,5-triaminobenzene and hydrolysing it into high-purity phloroglucinol
PHV Analytic 1511726*

Aromatic sulphones and their medical use
Glaxo Group 1511727*

Oxophenyl-cyclohexyl-propanolamine derivatives, production and use thereof in therapeutics
Sanofi-Aventis 1511728*

Histone deactylase inhibitors based on alphachalcogenmethylcarbonyl compounds
Errant Gene Therapeutics 1511729*

Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
Novartis 1511730*

Method for producing 4-haloalkyl nicotinic acid amides
Bayer CropScience 1511731*

Process for the preparation of quinoline derivatives
Active Biotech 1511732*

Pyrazole and pyrrole carboxamide insecticides
EI du Pont de Nemours 1511733*

Compounds, compsns and methods
Cyanokinetics; SmithKline Beecham 1511734*

Imidazole compounds and their use as ligands of the alpha adrenoreceptors
Pierre Fabre Medicament 1511735*

Therapeutic molecules and methods-1
Cortical Pty 1511736*

Aryloximes
Merck 1511737*

Treatment of fibroproliferative disorders using TGF-beta inhibitors
Scios 1511738*

Polymorphs of valsartan
Teva Pharmaceuticals 1511739*

Phenyl-thiophene type vitamin D receptor modulators
Eli Lilly 1511740*

Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgesics
Eli Lilly 1511741*

Kinase inhibitors
Cytopia Pty 1511742*

Pyrazole-derivatives as P38 kinase inhibitors
Pharmacia 1511743*

Bis-benzimidazoles and related compounds as potassium channel modulators
Icagen 1511744*

Protease inhibitors
SmithKline Beecham 1511745*

Process for imadazo(4,5-C)pyridin-4-amines
3M Innovative Properties 1511746*

Imadazo-pyridine derivatives as ligands for GABA receptors
Merck Sharp & Dohme 1511747*

8-fluoroimadzzo(1,2-A)pyridine derivatives as ligands for GABA receptors
Merck Sharp & Dohme 1511748*

Novel interleukin-1beta converting enzyme inhibitors
Procter & Gamble 1511749*

Process for the preparation of famciclovir
Teca Pharmaceutical Industries 1511750*

Pyrazolo(1,5A)pyrimidine compounds as antiviral agents
Neogenesis Pharmaceuticals 1511751*

Camptothecins with a modified lactone ring
Sigma-Tau Industrie Farmaceutiche Riunite 1511752*

Antimicrobial agents and uses thereof
Activbiotics 1511753*

Multimer forms of mono- and bis-acylphosphine oxides
Ciba Specialty Chemicals 1511754*

Improved inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
Albert Einstein College of Medicine of Yeshiva University 1513402*

Cardiac glycosides to treat cystic fibrosis and other IL-8 dependent disorders
Henry M Jackson Foundation for the Advancement of Military Medicine 1513403*

Intramyocardial injection of autologous bone marrow
Myocardial Therapeutics 1513404*

Analgesics
Ionix Pharmaceuticals; West Pharmaceutical Services Drug Delivery and Clinical Research Centre 1513493*

Film-shaped mucoadhesive administration form for administering cannabis active ingredients
LTS Lohmann Therapie-Systeme 1513494*

Modified release pharmaceutical formulation
AstraZeneca 1513495*

Immediate release pharmaceutical formulation
AstraZeneca 1513496*

Dosage forms and compsns for osmotic delivery of variable dosages of oxycodone
Alza Corp 1513497*

Method for modulation of drug release from multiphase implantable or insertable medical devices and a process for manufacturing such devices
Boston Scientific 1513498*

Ibuprofen suspension
Taro Pharmaceuticals 1513499*

Pharmaceutical preparations for oral administration, containing ion-exchange resins loaded with active ingredients and intrinsically viscous gelling agents as thickening agents
Bayer HealthCare 1513500*

Simple and multiple emulsions for decontamination of an organism or surfaces
Centre National de la Recherche Scientifique; Ecole Centrale de Paris; Universite de Paris-Sud XI 1513501*

Combination therapy for respiratory disorders
University of Southampton 1513502*

Extended release formulation of divaproex sodium
Ranbaxy Laboratories 1513503*

Sustained release oral dosage forms of gabapentin
Ranbaxy Laboratories 1513504*

An improved modified release preparation
FH Faulding 1513505*

Targeting system comprising uniformly-sized nanoparticles with at least one polymer and at least one positively-charged polysaccharide and preparation method thereof
Bioalliance Pharma 1513506*

Transdermal analgesic systems with reduced abuse potential
Alza Corp 1513507*

Gastroretentive drug delivery system comprising an extruded hydratable polymer
Euro-Celtique 1513508*

Nebuliser formulations of hehydroepiandrosterone and methods of treating chronic asthma or chronic obstructive pulmonary disease using compsns thereof
Epigenesis Pharmaceuticals 1513509*

The use of milnacipran for the treatment of tension-type headache
Head Explorer 1513510*

(2S)-2-amino-4-[2-[ethanimidoylamino]-ethyl]thio butanoic acid, a nitric oxide synthase inhibitor, in stabilised pharmaceutical dosage forms
SB Pharmco Puerto Rico 1513511*

Soluble stable pharmaceutical compsn for the administration of HIV protease for the preparation of concentrated pharmaceutical compsns for the administration of HIV protease inhibitors
Cristalia Produtos Quirinicos Farmaceuticos 1513512*

Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies
The University of Kentucky 1513513*

Lignan formulations
Hormos Medical Corp 1513514*

Substituted 4H-chromenes, 2H-chromenes, chromans and analogues of caspases and inducers of apoptosis and the use thereof
Cytovia; Shire BioChem 1513515*

Substituted 3-amino-thieno(2,3-B)pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
Boehringer Ingelheim Pharmaceuticals 1513516*

Formulation of nefopam and its use in the treatment of pain
Arakis 1513517*

Use of nefopam for the treatment of nausea or emesis
Arakis 1513518*

Use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidaemia and associated diseases
Novartis 1513519*

Substituted pyrrolines as kinase inhibitors
Janssen Pharmaceutica 1513520*

Pyranoindazoles and their use for the treatment of glaucoma
Alcon 1513521*

Methods of treating conditions associated with an EDG receptor
SRI International 1513522*

1,5-disubstituted imiadzolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of eye and bone diseases
Merck Frosst Canada; Bilot, Xavier; Young, Robert 1513523*

Ether substituted imidazopyridines
3M Innovative Properties Company 1513524*

Use of MGLUR5 antagonists for the treatment of GERD
AstraZeneca 1513525*

Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as HPPAR activators
SmithKline Beecham 1513526*

Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers
Takeda Pharmaceutical Co 1513527*

Pharmaceutical compsn containing stabilised amorphous form of donepezil hydrochloride
Krka Tovarna Zdravil 1513528*

Triple monoamine reuptake inhibitors for the treatment of chronic pain
Neurosearch 1513529*

Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
RheoGene 1513530*

Basic non-peptide bradykinin antagonists and pharmaceutical compsns therefrom
Menarini Richerche 1513531*

Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
Euro-Celtique 1513532*

Pharmaceutical active substance combination and the use thereof
Coestar, Carl-Fr. 1513533*

Compounds for increasing ABCA-1 expression useful for treating coronary artery diseases and atherosclerosis
CV Therapeutics 1513534*

Controlled release formulation of lamotrigine
Torrent Pharmaceuticals 1513535*

Use of compounds that stimulate CGMP
Bayer HealthCare 1513536*

Substituted porphyrins
Duke University 1513537*

Novel methods for the delivery of polynucleotides to cells
Mirus Corp 1513538*

Use of amphiphilic nucleoside phosphonoformic acid derivatives for the treatment of viral infectious diseases
Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum 1513539*

Pharmaceutical compsns comprising abacavir and lamivudine
Glaxo Group 1513540*

Method and compsn for preventing or alleviating symptoms of malabsorption from the gastrointestinal tract
NV Nutrica 1513541*

Anti-cancer and wound healing compsns
Kimberley-Clark Worldwide 1513542*

FAS peptide mimetics and uses thereof
The Trustees of the University of Pennsylvania 1513543*

Retrocyclins: antiviral and antimicrobial peptides
The Regents of the University of California; Lehrer, Bobert; Waring, Alan; Cole, Alexander; Hong, Teresa 1513544*

Methods and means to promote gut absorption
Vlaams Interuniversitair Instituut voor Biotechnologie 1513545*

Compsns for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
Insignion Holdings; Veritron 1513546*

Use of a parathyroid hormone peptide alagues for the treatment of vaginal atrophy
Holick, Michael 1513547*

Method for reducing obstructive hydrocephalus
UAB Research Foundation 1513548*

• Human prolactin antagonist-angiogenesis inhibitor fusion proteins
Greenville Hospital System 1513549*

• Implant having a long-term antibiotic effect
Aesculap 1513563*

• Sustained release of superoxide dismutase from implantable or insertable medical devices
Boston Scientific 1513564*

• Implantable or insertable devices for controlled delivery of a therapeutic agent
Boston Scientific 1513565*

• Implantable or insertable medical devices for controlled delivery of a therapeutic agent
Boston Scientific 1513566*

• Self-administered contraceptive injection of oily solution
Akzo Nobel 1513587*

• Use of new etonogestrel esters
Akzo Nobel 1513588*

• 1,5-disubstituted pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma
Merck Frosst Canada 1513589*